Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
36 hedge funds and large institutions have $13.3M invested in Vincerx Pharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
3% more funds holding
Funds holding: 35 → 36 (+1)
2% more capital invested
Capital invested by funds: $13M → $13.3M (+$315K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
+$158K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$64.6K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$30.4K |
| 4 |
Millennium Management
New York
|
+$16.9K |
| 5 |
Renaissance Technologies
New York
|
+$15.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$164K |
| 2 |
BlackRock
New York
|
-$27.1K |
| 3 |
TC
Tejara Capital
London,
United Kingdom
|
-$22.4K |
| 4 |
RC
RBF Capital
San Francisco,
California
|
-$11K |
| 5 |
Goldman Sachs
New York
|
-$10.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $28.2K | +$30.4K | +1,356 | New |
|
27
Northern Trust
Chicago,
Illinois
| $26.6K | – | – | – |
|
28
Morgan Stanley
New York
| $25.1K | +$1.61K | +72 | +6% |
|
29
Bank of Montreal
Toronto,
Ontario, Canada
| $14.1K | – | – | – |
|
|
GW
30
GW & Wade
Wellesley,
Massachusetts
| $11K | +$12.2K | +545 | New |
|
31
Two Sigma Investments
New York
| $10.9K | -$560 | -25 | -5% |
|
|
HCM
32
Hollencrest Capital Management
Newport Beach,
California
| $10.4K | – | – | – |
|
33
Bank of America
Charlotte,
North Carolina
| $3.02K | -$45 | -2 | -1% |
|
|
TRCT
34
Tower Research Capital (TRC)
New York
| $3K | +$336 | +15 | +11% |
|
35
Barclays
London,
United Kingdom
| $2.66K | – | – | – |
|
36
Wells Fargo
San Francisco,
California
| $124 | – | – | – |
|
|
RC
37
RBF Capital
San Francisco,
California
| – | -$11K | -563 | Closed |
|
VINC Hedge Fund Activity: Q1 2023 in Review
36 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q1 2023, worth a combined $13.3M — up 2.4% from $13M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new VINC positions and 1 closed out — a net gain of 1 holder — while 7 added to existing stakes and 6 trimmed.
The largest buyer was ExodusPoint Capital Management, adding an estimated $158K. The largest seller was Sabby Management, cutting an estimated $164K.
- 36 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q1 2023, up from 35 in Q4 2022.
- Funds reported $13.3M of Vincerx Pharma, Inc. Common Stock stock for Q1 2023, up 2.4% quarter-over-quarter.
- 2 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q1 2023 and 1 closed out, a net change of +1 holder.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q1 2023 was ExodusPoint Capital Management, an estimated $158K added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q1 2023 was Sabby Management, an estimated $164K sold.
Based on aggregated 13F filings for Q1 2023.